Related references
Note: Only part of the references are listed.Circulating Type-1 anti tumor CD4+ T cells are preferentially pro-apoptotic in cancer patients
Amy K. Wesa et al.
FRONTIERS IN ONCOLOGY (2014)
HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab
Suthinee Ithimakin et al.
CANCER RESEARCH (2013)
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Chunyan Gu-Trantien et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Circulating and Tumor-Infiltrating Myeloid-Derived Suppressor Cells in Patients with Colorectal Carcinoma
Bin Zhang et al.
PLOS ONE (2013)
Multiplexed characterization of cancer immune response in FFPE biopsies - initial performance of a new approach
Chichung Wang et al.
Journal for ImmunoTherapy of Cancer (2013)
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
Anupama Sharma et al.
CANCER (2012)
Dendritic cell-based vaccines: barriers and opportunities
Jessica A. Cintolo et al.
FUTURE ONCOLOGY (2012)
A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer
Gary K. Koski et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Pathological features and prognosis of different molecular subtypes of breast cancer
Guo-Sheng Wang et al.
MOLECULAR MEDICINE REPORTS (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M. A. Mahmoud et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Inhibition of ErbB2 by Herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line
Irem Dogan et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2011)
Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know
Steven A. Rosenberg
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Michael Kalos et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes
Rinke Bos et al.
CANCER RESEARCH (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer
Robert E. Roses et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Linda C. Benavides et al.
CLINICAL CANCER RESEARCH (2009)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides
Holden T. Maecker et al.
BMC IMMUNOLOGY (2008)
Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine:: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Asna Amin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates
Gabricla Alexe et al.
CANCER RESEARCH (2007)
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy
X-F Wen et al.
ONCOGENE (2006)
Herceptin sensitizes ErbB2 - Overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression
ES Henson et al.
CLINICAL CANCER RESEARCH (2006)
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration
Alejandro Wolf-Yadlin et al.
MOLECULAR SYSTEMS BIOLOGY (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells
MK Levings et al.
BLOOD (2005)
Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice
Y Sakai et al.
CANCER RESEARCH (2004)
Detection of low-frequency antigen-specific IL-10-producing CD4+ T cells via ELISPOT in PBMC:: cognate vs. nonspecific production of the cytokine
REM Guerkov et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma
UK Liyanage et al.
JOURNAL OF IMMUNOLOGY (2002)
HER2/neu in the management of invasive breast cancer
F Meric et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2002)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
